The article also says: "Beyond capacity challenges, the path to making an mRNA product in Australia involves other challenges, however, including access to fill-and-finish facilities to bottle the vaccines, as well as availability of qualified personnel to make the products at scale."
The article also says: "Beyond capacity challenges, the path to...
-
- There are more pages in this discussion • 422 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 11.0¢ | $1.103K | 10.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 248400 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 110410 | 2 |
View Market Depth
| Last trade - 10.34am 01/07/2024 (20 minute delay) ? |
| IDT (ASX) Chart |